Effect of oral zinc sulphate on serum lipids and lipoproteins in human subjects.
A controlled study was undertaken to evaluate the hypolipidemic effect of zinc. Ten stabilized patients of ischaemic heart disease (IHD) were given 200 mg of zinc sulphate orally thrice a day for one month (Test group). Ten other patients were given a placebo (Control group). Serum cholesterol, triglycerides, alpha-lipoproteins and beta-lipoproteins were measured before and after the treatment period. Test group showed a significant decrease in serum cholesterol and beta-lipoproteins, a significant increase in alpha-lipoproteins and no significant change in triglycerides. Control group showed no significant change in any parameter. These results show the potential value of zinc sulphate in the treatment of hyperlipidemia and IHD.